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AND TYPE I ERROR CONTROL1
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Public data repositories have enabled researchers to compare re-
sults across multiple genomic studies in order to replicate findings.
A common approach is to first rank genes according to an hypothe-
sis of interest within each study. Then, lists of the top-ranked genes
within each study are compared across studies. Genes recaptured as
highly ranked (usually above some threshold) in multiple studies are
considered to be significant. However, this comparison strategy of-
ten remains informal, in that type I error and false discovery rate
(FDR) are usually uncontrolled. In this paper, we formalize an in-
ferential strategy for this kind of list-intersection discovery test. We
show how to compute a p-value associated with a “recaptured” set
of genes, using a closed-form Poisson approximation to the distri-
bution of the size of the recaptured set. We investigate operating
characteristics of the test as a function of the total number of studies
considered, the rank threshold within each study, and the number
of studies within which a gene must be recaptured to be declared
significant. We investigate the trade off between FDR control and
expected sensitivity (the expected proportion of true-positive genes
identified as significant). We give practical guidance on how to de-
sign a bioinformatic list-intersection study with maximal expected
sensitivity and prespecified control of type I error (at the set level)
and false discovery rate (at the gene level). We show how optimal
choice of parameters may depend on particular alternative hypothe-
sis which might hold. We illustrate our methods using prostate cancer
gene-expression datasets from the curated Oncomine database, and
discuss the effects of dependence between genes on the test.
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1. Introduction. Given several independent genomic data sets which ad-
dress a similar question, it is common to compare the lists of the top-ranked
genes from each study. Genes selected as highly ranked in multiple studies
may be considered validated or replicated. Curated databases of gene lists
are available which include tools for comparing lists and intersecting lists
of top-ranked genes across multiple similar studies [Glez-Pena et al. (2008),
Culhane et al. (2010)]. The “correspondence at the top” concordance statis-
tic is an example of this approach Irizarry et al. (2005). Perhaps the most
well known example is the study by Tomlins et al. of gene expression in solid
tumors, Tomlins et al. (2005) which compared the top 10 genes from each of
132 cancer studies in a publicly available microarray data repository. Within
each study, the genes were ranked according to a statistic scoring potential
“fusion gene” properties, as such fusion genes are known to be important
drivers of malignancy in several hematologic cancers. Tomlins et al. targeted
a candidate gene list of 300 known cancer genes; any candidate gene which
ranked among the top 10 in two or more of the studies was considered to be
a potential hit. Two significant genes were found, one which ranked among
the top 10 in two different studies and another in five studies. For these
two genes, a fusion product was subsequently experimentally confirmed in
prostate cancer and these remain the only common fusion transcripts dis-
covered in an epithelial tumor.
In this paper we show how to conduct such an intersection-of-lists ap-
proach to assessing significance while controlling type I error (at the set level)
and false discovery rate (at the gene level). Given N independent studies,
there are two parameters which define a “hit”: the rank threshold, r, above
which a gene must lie in each study (r = 10 in the Tomlins example), and the
number of lists, n, among which a gene must be ranked (n= 2 in the Tom-
lins example) in order to be declared significant. Our first goal is to define
an exact p-value which is easy to compute, when assessing the intersection
of n lists of top-ranked genes, at rank r or above. This entails defining an
appropriate test statistic and corresponding hypothesis test, which we call
a list-intersection discovery test, as this is an “unsupervised” or discovery
approach. We apply these ideas to the related “supervised” case of an a priori
candidate gene list which is compared against N other independent studies,
as in Tomlins et al. (2005). Here the aim is to validate the genes appearing
in the researcher’s a priori list with a formal test of hypothesis. Following
Irizarry et al. (2005), we call this a list-intersection concordance test. We
then develop practical guidelines for choices of r and n which maximize the
expected sensitivity at a given false discovery rate (FDR), that is, which
maximize the expected proportion of true-positive genes that are declared
to be significant at a given FDR. We give example applications of both the
discovery and concordance test using data from the Tomlins study.
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To state the discovery problem more precisely, consider data from N in-
dependent (gene-expression) studies. Within each study, suppose T genes
are independent and are ranked according to a statistic, and consider the
list of the r top-ranked genes in each study. The set of genes which lie in the
intersection of n or more of these lists, Sn(r), are those genes “recaptured”
as significant at least n times across N independent studies. However, the
degree of confidence in this validation remains to be assessed. For example,
considering N = 6 independent studies, each with 10,000 possible genes, it
may be very likely that by chance alone at least 50 genes would be recap-
tured among the top r = 200 genes in n = 2 or more studies (as we shall
demonstrate, probability 0.84), somewhat likely that 5 or more genes would
be so recaptured across n = 3 studies (probability 0.02), and very unlikely
that any one gene would be recaptured in n = 5 out of 6 studies just by
chance (probability 0.0002). In this paper we show how to compute these
probabilities (these examples are computed in Section 2.2), how to assess the
statistical significance of the recaptured set for given r and n, and how to
estimate the false discovery rate within the recaptured set. The test statistic
we use is |Sn(r)|, the size of the intersection set; in the above three exam-
ples |Sn(r)| ≥ 50, 5 and 1, respectively. In making these computations we
have assumed the genes behave independently, which is no doubt not true
in practice, and this is addressed theoretically and in simulations in the last
section of the paper.
The paper is organized as follows: in Section 2 we derive the distribution
of the list-intersection test statistic under the null hypothesis and show how
to compute a p-value for a gene-set and how to estimate the within-set false
discovery rate (FDR). In Section 3 we derive the distribution of the list-
intersection concordance test statistic. In Section 3.2 we apply the test to
data in Tomlins et al. (2005). In Section 4 we discuss how to control the
type I error of the discovered set, and how to control the false discovery rate
of the genes within the discovered set. We give a strategy for finding good
choices of r and n (Section 4.2). In Section 5 we give an example of how to
mine a data repository for a “statistically significant” discovered gene set
while controlling the type I error at the set level and the within-set FDR.
Section 6 addresses what happens if independence on genes does not hold,
and then gives conclusions and future directions. Simulation studies, code,
and additional proofs are described in the supplemental article [Natarajan,
Pu and Messer (2011)].
2. The list-intersection discovery test. The list-intersection test com-
pares the top-ranked gene lists from multiple studies in order to discover
a common significant set of genes. Suppose we consider N studies, each of
which investigate T genes, and that the genes within a study are ranked
according to a prespecified scoring procedure which might be fold change,
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a between group t-test, or might differ from study to study. Consider the
list of “top r” genes within each study, and consider the set of genes, Sn(r),
which lie in n or more of these top-ranked lists. (We will often omit the de-
pendence on r for convenience.) In this section we find the expected count
EH0 |Sn| under the null hypothesis of random ranking of the genes. We show
that |Sn| has an approximately Poisson distribution under the assumptions
the genes within a study are independent, and that T ≫ r and E|Sn| ≪ r
where both T and r are large, and use this to compute a p-value.
2.1. Null distribution of |Sn(r)|, estimated FDR and p-values. For an
arbitrary gene g, let the Bernoulli trial Bg = 1 if the gene ranks among the
top r genes in n or more studies, with Bg = 0 otherwise. Then
|Sn|=
T∑
g=1
Bg.(2.1)
Let P 0n = P (Bg = 1) denote the associated probability under the null hy-
pothesis. (Note that we have suppressed the dependence of P 0n on r for
convenience.) While the Bernoulli trials Bg are not independent even un-
der the assumption of independent genes (given that one gene lies among
the top r genes, the next gene is less likely to do so), they are identically
distributed, and so it is immediate that
EH0 |Sn|= TP
0
n .(2.2)
To evaluate P 0n under the null hypothesis of random ranking among T
genes in each study, index the studies from i= 1 to N and again consider
an arbitrary gene g. Let Ai be the Bernoulli trial that counts a success
if g ranks among the top r genes in study i, with P (Ai = 1) = pi. Under the
null hypothesis, pi = r/T ≡ p0, and the Ai are independent. Let X count the
number of successes for gene g. Then X ∼ Bin(N,p0), and the probability P
0
n
that gene g is listed among the top r genes in n or more studies is given by
P 0n = P (X ≥ n),(2.3)
an easily computed binomial probability. Using (2.2) and (2.3), one may
then estimate the within-set FDR by comparing the expected number of
discoveries under the null hypothesis to the total number of discoveries made:
F̂DR = EH0 [|Sn|]/|Sn|.(2.4)
Under the null hypothesis of independent random ranking of the genes,
we can derive the distribution of |Sn|. Note that for large T with T ≫ r,
selection of the r top-ranked genes within a study has nearly the same dis-
tribution as random sampling with replacement. If, in addition, E|Sn| ≪ r,
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then Bg and Bh are approximately independent for any pair of genes g
and h. In this case |Sn| will have an approximate Binomial distribution with
parameters T and P 0n . If, in addition, T is large and P
0
n small, it follows
that the distribution of |Sn| is approximately Poisson with mean TP
0
n . We
consider the effects of correlation between genes in Section 6.1.
2.2. Example computations using the list-intersection statistic. Here we
show how to use (2.2) and (2.3) to compute the expected number of genes
recaptured just by chance, as well as the p-value of the size of the recaptured
set and the estimated FDR for genes within the set. These quantities depend
on the total number of studies considered, N , the depth of the top-ranked
list, r, and the number of lists intersected, n. Throughout we let T = 10,000.
We also investigate the quality of the Binomial and Poisson approximations
for these examples:
(i) As in the Introduction, consider that we have ranked T = 10,000
genes, and that the top r = 200 genes are the top-ranked set. Then, under the
null hypothesis of independent random ranking, p0 = r/T = 0.02. From (2.3),
given N = 6 studies to compare, the probability of seeing a given gene in
the top 200 from n= 2 or more studies is P 02 = 0.0057. It follows from (2.2)
that |S2(200)|, the number of genes captured in 2 or more studies, is then
approximately Poisson with mean TP 02 = 57.
To evaluate the accuracy of p-values computed from this Poisson approx-
imation, note that two of the three key assumptions, that T ≫ r and P 0n be
small, are met. However, E|S2|/r ≈ 0.30, so that E|S2| is not particularly
small compared to r. Suppose the observed value of |S2(200)| = 50. Then,
from simulation under the null hypothesis of random ranking, P (|S2(200)| ≥
50) = 0.86, compared to the corresponding Poisson p-value of 0.84, yielding
a relative error of 2.3%. Further examples show the simulated 95th percentile
of the null distribution is 68, while the Poisson approximation gives 70 (rel-
ative error, 2.9%). At 1% significance level, the relative error is 2.7% (simu-
lated value 73; Poisson approximation 75). Thus, the Poisson approximation
appears to work well in this case.
(ii) Continuing the example, if we require the genes to be recaptured in
three or more studies (so that n = 3 rather than 2), the mean number of
genes captured under the null is only 1.53. As in the Introduction, suppose
the observed value of |S3(200)| = 5. Under the null hypothesis of random
ranking the probability that 5 or more genes would be in the intersection
list is P (|S3(200)| ≥ 5) = 0.02, where |S3(200)| is Poisson with mean 1.53.
Thus, we would have seen a statistically significant event with a p-value of
0.02. The estimated within-set FDR would be 1.53/5, or 31%. Note that from
simulation, P (|S3(200)| ≥ 5) = 0.018, again demonstrating the adequacy of
the Poisson approximation.
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(iii) Now suppose only N = 4 rather than 6 total studies are considered,
and n= 2 as before. Then the expected number of genes captured by chance
falls by half, to a mean of 23 genes.
Again the relative error of the 95th and 99th percentiles of |S2(200)| from
the Poisson approximation is 3% (the simulated 95th percentile of the null
distribution is 31, while the Poisson approximation gives 32; the simulated
99th percentile is 34, while the Poisson approximation gives 35).
(iv) When N = 6 but the depth of the list is halved so that only the top
r = 100 genes are considered, the mean number of genes captured by chance
falls by 3/4, from 57 to 15. The relative approximation error of the Poisson
distribution is 0% for the 95th percentile, and 4% for the 99th percentile.
These examples show how to use the Poisson approximation to the dis-
tribution of Sn(r) to calculate p-values and FDRs. Over the range of pa-
rameters considered here, the Poisson approximation appears to be very
good. Additional simulations are reported in Section 5 and Section 1.1 of
the supplemental article [Natarajan, Pu and Messer (2011)].
3. The list-intersection concordance test. The concordance test evalu-
ates whether an a priori candidate list of m genes, say, from the researcher’s
new study, is significantly reproduced among the top r genes in N indepen-
dent ranked lists of genes, say, from other experiments or from the litera-
ture. Suppose each study investigates T genes and consider the set of genes,
Cmn (r), from the a priori candidate list which also lie in n or more of these
top-ranked lists. As before, we show that |Cmn | has an approximately Pois-
son distribution under the null hypothesis of independent random ranking
of the genes, however, with a different mean, under the assumptions that
T ≫ r and E|Cmn | ≪ r and both T and r are large.
3.1. Null distribution of |Cmn (r)|. Again, index the studies from i = 1
to N . Consider an arbitrary gene g drawn from the a priori list of m genes
of interest, and, as before, for study i let Ai be the event that gene g is
listed among the top r genes. Under the null hypothesis of random ranking
among T genes in each study, pi = r/T ≡ p0, as before. As in Section 2.1,
equation (2.3) gives P 0n , the probability under the null hypothesis that n or
more of the events A1, . . . ,AN occur simultaneously. Now consider the m
genes on the a priori list, and let Bg = 1 if the gth gene ranks among the
top r genes in n or more studies, with Bg = 0 otherwise. Under the null
hypothesis P (Bg = 1) = P
0
n , and as |C
m
n |=
∑m
g=1Bg, it is immediate that
E|Cmn |=mP
0
n(3.1)
under the null. Further, for large T with T ≫ r, selection of the r top-
ranked genes within a study has nearly the same distribution as random
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Table 1
Example: expected and observed number of recaptured candidate genes, p-values and
estimated FDR within the recaptured set. Data from Tomlins et al. (2005); T = 10,000
genes across N = 132 studies, with the top r = 10 genes considered from each study. The
length of the a priori candidate gene list is m= 300. The recapture rate n varies from 2
to 5; n= 2 was the choice used in Tomlins et al. (2005)
n = 2 n = 3 n = 4 n= 5
E|Cn| under null 2.5 0.11 <0.01 <0.01
Observed Cn {ERBB2, ERG, ETV1, IRTA1} ERG ERG ERG
Observed |Cn| 4 1 1 1
p-value 0.25 0.006 7× 10−6 5× 10−9
Estimated FDR 0.63 0.11 <0.01 <0.01
sampling with replacement. If in addition E|Cmn | ≪ r, then Bg and Bh are
approximately independent for any pair of genes g and h. In this case |Cmn |
will have an approximate Binomial distribution with parameters m and P 0n ,
which in turn is approximately Poisson with mean mP 0n for m large and P
0
n
small.
3.2. Example test using data from Tomlins et al. We apply these compu-
tations to the data from Tomlins et al. (2005). They considered the Cancer
Gene Census [Futreal et al. (2004)] published list of 300 genes known to be
involved in cancer, and compared this candidate gene list across 132 studies
from the Oncomine [Rhodes et al. (2007)] repository of microarray data.
Within each study, they ranked all genes according to a score characteristic
of a fusion gene. They then looked for the occurrence of any candidate can-
cer genes among the 10 top-ranked genes in each study, and for each cancer
gene, reported how many times it was “captured” in a top-10 list. To define
parameters, each microarray platform interrogated about 10,000 expressed
genes. Thus, we have T = 10,000 genes across N = 132 studies, with the top
r = 10 genes considered from each study. The length of the a priori list is
m= 300.
We applied (2.3) and (3.1) to find the expected number of cancer genes
which appear in the intersection of n multiple lists under the null hypothesis
of independent random ranking, for n ranging from 2 (the case considered
by Tomlins et al.) to 5. These results are given in Table 1, in the row la-
beled E|Cn|. We give the set of actual genes found by Tomlins et al. in the
intersection of n or more lists (the observed set Cn), taken from their sup-
plementary Table S1. We also record the count of cancer genes recaptured n
or more times (the observed count |Cn|). We then compute the p-value for
each value of n, computed as the probability that a Poisson variate with the
given mean would lie above the observed value of |Cn|, and the estimated
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FDR within each recaptured set. Notably, the observed set of cancer genes
which is in the intersection of 2 or more lists, the set considered by Tomlins
et al., has a p-value of 0.25, indicating it is plausible that this many genes
would reappear just by chance. Four genes were “discovered” in this recap-
tured set, while the expected number recaptured under the null is 2.5 for
an estimated FDR of 2.5/4 or 63%. However, the p-values attached to the
single gene ERG, which reappears in 5 studies, is highly significant. Both
ERG and the related ETV1 were subsequently validated as fusion genes.
This example illustrates how to compute the p-value for the size of an
observed set of concordant genes. However, notice that multiple p-values are
presented in Table 1, corresponding to multiple choices of r and n. Unless
we specify r and n in advance, we are open to charges of data snooping,
that is, of tailoring the choice of r and n to the results they yield in a given
data set, rendering the nominal p-values invalid. Thus, this example also
highlights the need for a strategy for choosing r and n, and, importantly,
the need to specify the choice of r and n before the analysis is carried out.
We discuss these issues in the remainder of the paper.
4. Control of type I error and within-set FDR. For a given prespecified
choice of r and n, the list-intersection test will declare a gene set to be signif-
icant only if |Sn(r)| [or |C
m
n (r)|] has a p-value below the stated significance
level α. This procedure will strictly control the type I error rate; that is,
under the null model, the probability will be at least 1−α that no gene set
will be declared to be significant. Given a statistically significant gene set,
it remains to investigate the FDR within set, and the expected proportion
of true positive genes that are captured (the expected sensitivity).
Importantly, as noted above, control of type I error requires both n and r
to be specified in advance. For example, there may be several sets Sn(r) with
p-values falling below any given significance level, and post hoc selection of
one or more of these sets without correction for multiple testing would of
course leave both the type I error and the set-level FDR uncontrolled. In
addition, failure to prespecify r and n is likely to lead to data snooping, in
which the chosen r and n are consciously or unconsciously tailored to yield
the most “interesting” set of selected genes. Thus, it remains to consider
how to make good a priori choices of r and n. In this section, we give an
example which illustrates how good choices of r and n may depend on which
particular alternative hypothesis holds, and then propose a general design
strategy. We leave as future work discussion of the more computationally
and mathematically involved data-driven strategies to control the FDR.
4.1. Example choices of r and n: Expected sensitivity and false discovery
rate. Different choices of the threshold r and the recapture rate n will
trade off between an increased false discovery rate within the set Sn(r)
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and increased power to capture any truly positive genes. For example, for
fixed n, as r increases and more genes are included in the set of “top-r”
genes, any truly significant genes (“true positives”) will be more likely to be
selected within each study and thus more likely to land in the intersection
set Sn(r). However, at the same time more null genes will be captured,
thereby potentially increasing the FDR within Sn(r), and possibly reducing
power to call Sn(r) a statistically significant set. Good choices for r and n
will evidently depend on how many truly positive genes exist, as well as
the effect size for each, as the latter determines the probability that a given
positive gene rises to the top of the list.
To illustrate these trade-offs, in Table 2 we compute the expected num-
ber of true discoveries and false discoveries for several choices of r and n,
under two simple alternative hypothesis scenarios. We considered N = 4 in-
dependent studies, each investigating T = 10,000 genes. We assume that the
statistic used to rank the genes has an approximately normal null distribu-
tion, such as a two sample t-statistic or a maximum likelihood statistic. We
assume a total of tp genes are true positives, and for each such gene, the
statistic is assumed to be normally distributed with mean µ and standard
deviation 1. We constructed two scenarios: alternative I had 25 true positive
genes, each upregulated by 3 standard deviations as compared to the null
genes, with the remaining T − tp constituting the null genes. In alterna-
tive II, we considered tp= 2 true positive genes, each with expression levels
upregulated by 4 standard deviations as compared to the null genes. Thus,
alternative I has multiple significant genes, each with moderate effect-sizes,
and alternative II has a few true hits with large effect-sizes. Under each of
these illustrative alternative hypotheses, we computed the expected number
of null and significant genes recaptured by the list-intersection statistic. The
mathematical argument for these expectations uses an argument from Feller
(1957) and is given in the supplement (Section 2) [Natarajan, Pu and Messer
(2011)]. For our two chosen scenarios, and for given r and n, Table 2 displays
the FDR within the intersection gene set as well as the expected sensitivity
(the expected proportion of true-positive genes that are captured). We con-
sidered recapture rates n from 2 to 4, and within-study thresholds r from
500 to 10.
For alternative hypothesis I (25 true-positive genes, each with 3σ up-
regulation), when n = 2, a high expected sensitivity can be achieved by
choosing r to be large. For example, r = 500 has an expected capture rate
of 24.93 true positives out of 25 total, for an expected sensitivity of 99.7%.
However, this is at the cost of an FDR of over 80%, as the expected num-
ber of false positives is over 128 with a total expected set size of 153.36.
Hence, the pair r = 500, n = 2 does not appear to be a good choice here.
Lowering r from 500 to 100 reduces the expected number of false positives
to 4 while maintaining the expected number of true positives captured at
10 L. NATARAJAN, M. PU AND K. MESSER
Table 2
Expected sensitivity (ESns) and FDR under different alternative hypotheses and choices
of r (within-study significance threshold), and n (recapture rate)
Recapture-rate (n) r = 500 r = 100 r = 50 r = 25 r = 10
Alternative hypothesis I: # of true positive genes = 25, each with 3-σ upregulation
as compared to null genes
2 EFP 128.43 3.99 0.71 0.10 0.003
ETP 24.93 23.36 21.02 16.91 9.05
ESns 0.99 0.93 0.84 0.68 0.36
FDR 0.84 0.15 0.03 0.006 <0.001
3 EFP 4.21 0.02 0.002 <0.001 <0.001
ETP 23.90 17.42 12.65 7.54 2.24
ESns 0.96 0.70 0.51 0.30 0.09
FDR 0.15 0.001 <0.001 <0.001 <0.001
4 EFP 0.05 <0.001 <0.001 <0.001 <0.001
ETP 17.06 6.94 3.64 1.47 0.22
ESns 0.68 0.28 0.15 0.059 0.009
FDR 0.003 <0.001 <0.001 <0.001 <0.001
Alternative hypothesis II: # of true positive genes = 2, each with 4-σ upregulation
as compared to null genes
2 EFP 139.14 5.70 1.38 0.32 0.04
ETP 2.00 2.00 2.00 1.99 1.95
ESns 1.00 1.00 1.00 1.00 0.98
FDR 0.99 0.74 0.41 0.14 0.02
3 EFP 4.76 0.04 0.005 <0.001 <0.001
ETP 2.00 1.97 1.93 1.85 1.65
ESns 1.00 0.99 0.97 0.93 0.83
FDR 0.70 0.02 0.002 <0.001 <0.001
4 EFP 0.06 <0.001 <0.001 <0.001 <0.001
ETP 1.93 1.64 1.44 1.19 0.84
ESns 0.97 0.82 0.72 0.60 0.42
FDR 0.03 <0.001 <0.001 <0.001 <0.001
Note: N = 4 independent studies; T = 10,000 genes measured in each study; EFP =
expected # of false positives; ETP = expected # of true positives; ESns = ETP/# true
positives; FDR= EFP/(EFP +ETP).
about 23 out of 25 (92% expected sensitivity); thus, (r = 100, n= 2) appears
to be a reasonable choice. Lowering r further achieves a lower FDR, but at
the cost of lower expected sensitivity: with n= 2 as r decreases from 50 to
10, the expected sensitivity decreases from 84% to 36%. A better trade-off
would be to require a larger recapture rate with n = 3 while maintaining
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Fig. 1. Expected sensitivity at r(n) versus recapture rate n, given N studies in total and
FDR≤ 0.01, under two alternative scenarios. For each recapture rate n, the expected sen-
sitivity at the optimal threshold r(n) is plotted. The filled circle represents the maximum
expected sensitivity achievable for a given N . As expected, sensitivity increases as the total
number of studies N increases. The recapture rate (n) and threshold [r(n)] which maxi-
mize sensitivity represent the optimal design choices which control FDR at the prescribed
rate. Here # of features/genes = T = 10,000, and FDR≤ 0.01; the value of r(n) is from
Table 3. Left: alternative I: 25 true-positive genes each with effect-size= 3σ. Optimal de-
sign for (i) N = 4 at n= 3, r = 195; (ii) N = 6 at n = 4, r = 384; (iii) N = 8 at n = 5,
r = 575; (iv) N = 10 at n = 6, r = 755. Right: alternative II: 2 true-positive genes each
with effect-size 4σ. Optimal design for (i) N = 4 at n = 3, r = 81; (ii) N = 6 at n = 4,
r = 194; (iii) N = 8 at n= 5, r = 332; (iv) N = 10 at n= 6, r = 475.
r = 500, as this combination maintains a sensitivity of 95.6% (ETP = 23.9
out of 25) while reducing false discoveries (EFP= 4.2 and FDR= 15%). Re-
quiring a recapture rate of 4 out of 4 studies is too stringent for the scenario
considered here. Thus, either (r = 100, n = 2) or (r = 500, n = 3) appear to
be good choices for alternative hypothesis I; both have expected sensitivity
over 90% and FDR under 15%. Note that it may not always be possible to
achieve high sensitivity and low FDR; in this case, as is evident in Figure 1
below, the number of studies N must be increased.
For alternative hypothesis II (2 true positive genes, each upregulated
by 4σ), for a recapture rate of n = 2, thresholds of r = 500,100 or 50 all
have expected sensitivity of 100%, but also have FDR over 40%. (However,
note that the number of false discoveries may not be prohibitive.) A cutoff
of r= 25 or r= 10 gives better control of the FDR, while maintaining a high
expected sensitivity. When n= 3, stringent thresholds such as r = 25 or 10
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result in capture of fewer true positives, whereas setting r= 100 appears to
be a good trade-off. Again, requiring a recapture rate of n= 4 reduces the
expected sensitivity, so the reasonable pairs among those considered appear
to be either (r = 100, n= 3) or (r = 10, n= 2).
We have illustrated how equations (2.3) and Supplement (2.1) [Natarajan,
Pu and Messer (2011)] can be used to calculate the expected number of true
and false positives, and FDR and expected sensitivity for various postulated
hypotheses. In the next section we examine how these methods might be
applied when designing a bioinformatic search to test a priori hypotheses of
interest.
4.2. Choosing r and n to maximize sensitivity, with FDR≤ q. The ex-
ample in Section 4.1 illustrates that the best choice of threshold r and recap-
ture rate n will depend on the number of true positive genes, as well as the
effect size for these genes. These considerations suggest how to design a list-
intersection test: given an acceptable FDR q, find r and n that maximize
the expected sensitivity while maintaining the gene-wise FDR≤ q. This can
be computed for a prespecified alternative hypothesis which postulates tp
true positive genes and corresponding effect-sizes as outlined below:
(1) Set an acceptable FDR = q.
(2) For each possible recapture rate n = 1,2, . . . ,N , find the maximum
threshold r(n) which still maintains FDR< q:
(a) For each r = 1, . . . , T :
(i) compute the expected number of recaptured false positive genes
EFP(n, r) = (T − tp)P 0n(r) [see Supplement equation (2.1)].
(ii) Given tp true positive genes and their effect-sizes, calculate
ETP(n, r), the expected number of recaptured true positive
genes. This can be obtained using Supplement equation (2.1)
as ETP(n, r) =
∑tp
a=1P
a
n (r).
(iii) Calculate FDR(n, r) as EFP(n,r)EFP(n,r)+ETP(n,r) .
(b) Let r(n) = maxTr=1{r|FDR(n, r)< q}.
(3) For each pair (n, r(n)), calculate its expected sensitivity, ETP(n, r(n))/tp.
(4) Choose the optimal pair, (n, r(n)), as the pair for which this expected
sensitivity is maximized.
To illustrate this strategy, we again examined the two alternative scenarios
discussed in Section 4.1. We set T = 10,000, as before, and let N vary from 4
to 10 studies. We bounded the FDR by q = 0.01. Table 3 lists the maximum
threshold r(n) which satisfies the FDR bound, as obtained from step 2 of the
above algorithm, for each possible recapture rate n. Note that r(n) increases
rapidly with increasing n. For example, under alternative hypothesis I, with
N = 4 studies and n= 2, the maximum threshold which maintains the FDR
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Table 3
The maximum threshold r(n) that satisfies FDR≤ 0.01, for a given number of studies N
and recapture rate n. Two alternative scenarios, T = 10,000 genes. Expected sensitivity
of the test at the maximum threshold is plotted in Figure 1, as a function of n
Total # of studies (N)
Recapture rate (n) 4 6 8 10
Alternative hypothesis I:
25 significant genes, each upregulated by 3-σ
2 30 24 20 18
3 195 126 95 77
4 683 384 270 210
5 – 869 575 434
6 – 1698 1034 755
Alternative hypothesis II:
2 significant genes, each upregulated by 4-σ
2 7 5 4 3
3 81 48 34 27
4 373 194 133 102
5 – 513 332 247
6 – 1123 659 475
cutoff is r(2) = 30, whereas if we consider intersections across all 4 studies
(i.e., n= 4), the maximum threshold is, as expected, larger at 683, since null
genes will be less likely to be recaptured across all studies. Note that r(n)
decreases as the number of studies N increases since the chance of a false
positive increases with the total number of studies and, hence, the size of
the recaptured list would need to be smaller to satisfy the prespecified FDR.
For each given number of total studies N , Figure 1 plots the expected
sensitivity, ETP/tp, against n for the optimal r(n) from Table 3. Given N
studies in total, the pair (n, r(n)) that maximizes sensitivity would be the
optimal a priori design choice for the study. For instance, under alterna-
tive hypothesis I and an FDR cutoff of 0.01, with N = 4 total studies, the
maximal expected sensitivity of ∼84% is achieved at recapture rate n= 3,
which from Table 3 is achieved at threshold r(3) = 195. The other two sce-
narios corresponding to (n, r(n)) = (2,30) or (4,683) achieve an expected
sensitivity of less than 80%. Hence, for alternative I and 4 total studies
[n = 3, r(3) = 195] is the optimal design choice. Note that under a given
alternative, as the total number of studies N increases, the best choice of
recapture rate n increases, as does the expected proportion of true positive
genes recaptured [the expected sensitivity at the optimal choice of (n, r(n)].
The calculations in Table 3 and Figure 1 illustrate how a good choice
of r and n involves maintaining control of the FDR while maximizing the
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chance of capturing true positive genes. The best choice of the pair (n, r(n))
of course depends on whether one expects many significant genes with small-
moderate effect sizes similar to alternative I, or few differentially expressed
genes at large effect sizes, similar to alternative II. For a given alterna-
tive hypothesis, our design strategy chooses the optimal combination of r
and n which maximizes the expected sensitivity, while controlling the FDR
at the desired level. Note that, if the expected sensitivity at the optimal pair
(n, r(n)) is not satisfactory, then either the number of studies considered N
must be increased or the desired FDR level must be relaxed.
If multiple alternatives are proposed with no clear “winner,” the above
procedure can be used to choose the optimal design for several proposed
alternatives. Then a Bonferroni correction could be applied, and the gene-
sets that pass a Bonferroni corrected significance level would be candidates
for further research. Specifically, for a given alternative and optimal de-
sign choice (n, r(n)), a p-value can be calculated for each |Sn(r(n))| the test
statistic of the observed data. This p-value might be computed using the ap-
proximate Binomial or Poisson distributions (Section 2) or via simulation.
Then for m possible alternatives, and a significance level α, the gene-sets for
which the corresponding p-values are less than α/m are considered “signifi-
cant.” This procedure strictly controls the type I error rate on the selected
significant sets. Thus, under the null model, the probability is α or less of
declaring a set of genes to be significant.
5. Example: Mining the Oncomine database for candidate fusion genes
in prostate cancer. To illustrate our methods, we carried out an exam-
ple list-intersection discovery study using the publicly available Oncomine
database [Rhodes et al. (2007)], as in the original Tomlins study [Tomlins
et al. (2005)]. We identified 4 suitable microarray gene expression prostate
cancer studies [Dhanasekaran et al. (2004), Lapointe et al. (2004), Tiwari
et al. (2003), Tomlins et al. (2006)]; our selection criterion was that all use
a similar cDNA microarray platform, and, as is common in such studies
[Tomlins et al. (2005)], we assumed that ∼10,000 genes would be expressed.
Thus, we have N = 4 and T = 10,000. Note that here, unlike in Tomlins
et al. (2005), we are conducting a genome-wide discovery test, rather than
a concordance test based on a list of candidate cancer genes. A second major
difference is that Tomlins et al. considered N = 132 studies across all cancer
types and all platforms. Of course, Tomlins et al. used an ad hoc strategy
to select interesting sets of genes for validation, rather than the statistically
motivated use of p-values we are illustrating here. In this setting we know
there to be least two true positive genes (the fusion genes identified in Tom-
lins et al.), and we are interested to see whether our a priori search strategy
will find them.
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Table 4
List-intersection discovery of fusion-gene candidates across N = 4 independent prostate
cancer studies. The test statistic |Sn(r)| is the observed number of genes that are ranked
among the top r genes in at least n studies; p-value represents the probability of
observing |Sn(r)| or more genes under the null hypothesis of independent random
ranking. The entry in bold corresponds to our a priori choice of n= 3, r = 81; as the
p-value for this entry is less than 0.05, the corresponding gene set is declared significant
# of studies (n) r = 100 r = 81 r = 50 r = 25 r = 10
|S2(r)| 10 6 4 4 2
2 p-value 0.08 0.20 0.06 0.0006 0.002
est.FDR∗ 0.59 0.65 0.37 0.09 0.03
|S3(r)| 1 1 1 1 1
3 p-value 0.04 0.02 0.005 0.0006 <0.0001
est.FDR∗ 0.04 0.02 0.005 0.0006 <0.0001
|S4(r)| 0 0 0 0 0
4 p-value 1 1 1 1 1
∗est.FDR = estimated FDR=E|Sn(r)|/|Sn(r)|.
We set the significance level to α= 0.05. We next will prespecify the pair
(n, r(n)), in order to avoid data snooping. Thus, under the null hypothesis
there would be only 5% probability that the study will declare any gene set
to be significant (see example in Section 3.2 and Section 4). As discussed
in Section 4.2, good choice of r and n depends on the particular alternative
hypothesis postulated. Because in this somewhat artificial setting we know
that fusion genes are rare and that at least two exist, alternative hypothe-
ses II (see Table 2) with 2 significant genes, each with an effect-size of 4, is
a reasonable choice for our study design. As in Table 2, we chose a stringent
FDR cutoff of 0.01, with the rationale that then all discoveries within a sig-
nificant set are likely to be true. Under these conditions, the optimal design
choice is (n = 3, r = 81), so that the set of genes S3(81) will be tested for
statistical significance (Table 3 and Figure 1).
Next, within each of the 4 identified prostate cancer studies, we ranked
the genes according to the “cancer outlier profile analysis” (COPA) pro-
cedure implemented in the Oncomine website [Rhodes et al. (2007)]. This
statistic measures “fusion-like” properties, and was used by Tomlins et al.
(2005). We computed the observed test statistic |S3|= |S3(81)| with N = 4
(Section 2) by counting the number of genes that were among the top 81
genes in at least 3 studies (Table 4). As seen in Table 4, the set S3(81)
contained 1 “hit.” To compute the associated p-value, we obtained the ex-
pected value of |S3(81)| under the null hypothesis as 10,000P
0
3 (81) = 0.021
using equation (2.3). Then the probability that a Poisson variate with mean
0.021 will exceed 4 is 0.02, giving the p-value reported in Table 4. Thus, we
declare the set S3(81) to be a statistically significant set. The single gene in
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the set S3(81) is ERG, a gene also found by Tomlins et al. in their study,
and this would be the single gene recommended for further investigation
from our study. At the stringent within-set FDR, we would have confidence
at about the 95% level that this was not a false positive result.
To gain additional insight, Table 4 presents p-values and FDRs for re-
captured sets over a range of thresholds r and recapture rates n. Note that
only S3(81) (Table 4) is considered a discovery according to our prespecified
analysis strategy; other sets could be presented as exploratory descriptive
results. For completeness we also examined the four genes corresponding to
|S2(25)|, as this had a highly significant p-value and a reasonable 9% FDR:
these are ERG, ETV1, EST and VGLL3, of which the first two were val-
idated as participants in a fusion gene by Tomlins et al. (2005). Thus, by
setting our FDR to the stringent level of 0.01, we accomplished the goal of
identifying a significant set which contained no false discoveries, however,
we missed one of the truly positive genes. Since validation of such bioinfor-
matic searches using rtPCR or other experimental techniques is expected,
applying a less stringent a priori FDR may be a reasonable approach.
To investigate the adequacy of the Poisson approximation, the p-values
in Table 4 were also verified by direct simulation as in Supplement Sec-
tion 2.1 [Natarajan, Pu and Messer (2011)]. The p-value for the observed
|S3(81)| = 1 (Table 4) via direct simulation was 0.0188 compared to the
Poisson approximation p-value of 0.0209. Considering the observed counts
|S2(r)| in Table 4, the p-values derived from the simulated null distribu-
tion of S2(r) were 0.0775,0.2001,0.0602, 0.0004 and 0.0018, respectively, for
the corresponding thresholds r of 100,81,50,25 and 10. Thus, the Poisson
approximation p-values and simulated p-values show good concordance.
6. Discussion.
6.1. Dependence between genes. In this paper we have assumed indepen-
dence of the genes within each study, however, in fact, expression levels may
be positively or negatively correlated between genes. Importantly, our strat-
egy for study design (i.e., for choice of r and n, given in Section 4) depends
only the mean of the test statistic |Sn|, which is unchanged under arbitrary
dependence. [To see this, note that if genes g and h are correlated, (2.2)
and (2.3) still hold.] However, correlation between genes will induce corre-
lation between the Bernoulli trials in expression (2.1), and, thus, p-values
computed under the assumption of independence under the null hypothesis
may no longer be correct. How to adjust for correlation between genes in
the analysis of gene expression studies is an active area of research [Efron
(2010), Benjamini and Yekutieli (2001), Sun and Cai (2009)]. Here we give
some quantitative guidance in the current setting, using simulation and by
considering theoretical cases of extreme dependence. More detailed analysis
will be the subject of future work.
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First, it is easy to see that negative correlation between genes may be
generally expected to reduce, and positive correlation to increase, p-values
as compared to the independent case. This is because correlation between
genes will induce correlation between the Bernoulli trials Bg in (2.1). The
variance of the sum will be correspondingly decreased or increased with the
mean remaining unchanged, rendering the distribution of |Sn(r)| either more
or less concentrated about its mean. It thus is most important to consider
the effect of positive correlation between genes because this will potentially
increase p-values and thus type I error, if p-values are computed under the
(incorrect) assumption of independence. The magnitude of the perturbation
to p-values clearly depends on both the number of correlated genes and
the strength of their correlation, while the exact perturbation depends on
the joint distribution of the correlated genes. Simulation studies reported
in the supplemental article (Section 1.2) [Natarajan, Pu and Messer (2011)]
show that moderate correlation (half of genes with weak correlation or a few
genes with strong correlation) does not appear to appreciably affect p-values.
Further support for these observations is found in the literature on models
for correlated Bernoulli trials, of which [Yu and Zelterman (2002), Gupta
and Tao (2010)] give relevant examples.
Quantitative insight on the potential magnitude of a perturbation can be
gained by considering the following extreme model: suppose the T genes can
be partitioned into modules of size m, where two genes within a module have
correlation ρ > 0 but any two genes in different modules are independent.
In the limiting case with ρ= 1, it is easy to see that |Sn(r)| has the same
null distribution as the statistic |mS˜n(r/m)|, where the distribution of |S˜n|
is computed using T˜ = T/m independent genes, and is thus approximately
Poisson with mean TP 0n/m. It follows that, under this model, |Sn(r)| has
unchanged mean, variance inflated by a factor of m, and that corrected
probabilities can be computed using the relation
P (|Sn|> x) = P (|S˜n|> x/m).(6.1)
As the postulated within-module correlation decreases from ρ = 1 toward
zero, the correct tail probabilities will smoothly interpolate from the correc-
tion given in (6.1) to the original values as computed in Section 2.1 under
independence. Thus, given correlated gene modules of postulated maximum
sizem, relation (6.1) might be used to give a conservative ballpark correction
to computed p-values.
An example can be computed using the data in Table 4, Section 5. For
example, four genes were recaptured by S2(25) (line 1 of Table 4), which
had a p-value of 0.0006 under the null hypothesis of independent random
ranking of genes. Suppose we wondered if correlation under the null hy-
pothesis would be sufficient to account for the observed data. After con-
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sideration, suppose we decided there were several pairs of strongly corre-
lated genes, so that we wanted to conservatively adjust for many corre-
lated gene modules of size 2, so m = 2. As before, p0 = r/T = 25/10,000
and P 02 = P (X ≥ 2) = 3.74 × 10
−5, so that under independence |S2(25)| is
approximately Poisson with mean TP 0n = 0.374. However, under the corre-
lated model with ρ= 1, |S2(25)| is distributed as |2S˜2(25)|, where |S˜2(25)|
is approximately Poisson with mean TP 0n/2 = 0.187. The p-value adjusted
for correlation would be P (|S˜n| ≥ 4/2) = 0.015. Thus, the maximum correla-
tion assuming pair-wise modules would be unable to completely account for
the observed data. Several simulation examples showing the effect of other
correlation structures are presented in the Supplement [Natarajan, Pu and
Messer (2011)].
6.2. Conclusions and future directions. Public repositories of genomic
data continue to grow, and list-intersection approaches similar to those con-
sidered here are likely to become even more common in the future, as several
repositories of curated gene lists have recently been published which include
tools for comparing lists and intersecting lists of top-ranked genes across
multiple similar studies [Glez-Pena et al. (2008), Culhane et al. (2010)]. The
primary statistical challenges for analyzing data from such repositories are
controlling the number of false positive results and maintaining a valid ba-
sis for inference when combining multiple studies [Benjamini, Heller and
Yekutieli (2009)].
A well-established method for pooling results across multiple studies is
meta-analysis. This approach is usually conducted gene-by-gene, and pro-
duces a combined p-value (or effect-size) for each gene [Zaykin et al. (2002),
Benjamini and Heller (2008), Garrett-Mayer et al. (2008), Pyne, Futcher and
Skiena (2006)]. However, under this approach it is possible that a significant
gene can be declared based on a few studies which display large effects, with
null effects observed in most studies, and this can lead to high false positive
rates [Pyne, Futcher and Skiena (2006)]. Garrett-Mayer and others [Garrett-
Mayer et al. (2008)] discuss the importance of first identifying genes that are
consistently measured across different microarray platforms, which is clearly
a useful preliminary analysis for reducing false positives. There is evidence
that rank-based approaches may be more robust and better guard against
false discoveries, while maintaining adequate power, compared to more tra-
ditional methods of meta-analysis [Hong and Breitling (2008)]. Formal or
informal rank-based meta analyses for combining effect sizes across multi-
ple studies have been proposed in the applied and methodological literature
[Chan et al. (2008), Jeffries et al. (2009), Deng et al. (2008), Miller and
Stamatoyannopoulos (2010)].
Our approach compares within-study ranks to a common threshold, and is
an effort to explore the inferential basis of the list-intersection approach. We
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provide exact formulas which allow examination of power and false discov-
ery rates. Our rank-threshold method does not combine individual per-gene
effect sizes, such as ranks, across multiple studies. Instead, we evaluate the
entire set of genes recaptured as above a rank threshold across multiple stud-
ies. Loosely speaking, this is akin to acceptance sampling procedures, where
a “lot” [i.e., the set Sn(r) in our notation] may be deemed “acceptable” if the
number of “defectives” (i.e., false discoveries) is below some level (defined by
the FDR). However, a salient point in our setup is that many “lots” [Sn(r)]
may be acceptable, in that they satisfy the FDR criteria. How to choose
among these multiple “acceptable” gene-sets is a a major focus of our work.
We discuss expected sensitivity of the gene-sets, and also obtain a p-value
per recaptured set, with tight control of the set-wise type I error rate. In this
sense our method is more stringent than an approach which combines gene-
by-gene effect sizes across studies. Our set-based method may also provide
tighter control of gene-level type I error and false discovery rates, although
this is the subject of future research.
In related work [Pyne, Futcher and Skiena (2006)], a pooled p-value is
calculated together with a consensus parameter defined as the number of
studies in which a feature has to be declared significant before it is con-
sidered significantly validated across studies. Thus, the consensus parame-
ter plays a similar role as our recapture rate n. Pyne, Futcher and Skiena
(2006) describe results for different values of such consensus parameters but
do not give guidelines on how to choose this parameter. Our work provides
the applied practitioner with p-values and expected number of false posi-
tives under various choices for within-study significance thresholds r and
recapture rates n, which could be used to guide decisions on significant
“gene-sets.”
Another method, the partial conjunction hypothesis test [Benjamini and
Heller (2008)], uses a p-value threshold to consider among how many stud-
ies out of N a given gene is found to be significant at a given level, where
each study addresses a different research hypothesis. For each gene g, the
set of hypotheses that the gene is null in n or fewer studies is simultane-
ously tested, for 1≤ n≤N . A general data-driven method for controlling the
FDR across all genes is presented, where the number of false discoveries is
defined as the number of genes which have been called significant in at least
one study in which the gene was truly null. In this setting the studies may
address differing alternative hypotheses, and the focus is on the situation
where a gene can be truly null in some but not other studies, and where this
may differ from gene to gene. Thus, it is of interest to ascertain for each gene
in which studies among all N considered it is truly significant. This differs
from the scenario considered in the present paper, in which the studies are
assumed to each test the same hypothesis. In the setting of Benjamini et al.
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power necessarily declines as the total number of studies N increases [Ben-
jamini and Heller (2008)]. This is in contrast to our Figure 1, in which the
expected sensitivity increases with the total number of studies N . Benjamini
et al. have the advantage, however, of controlling the false discovery rate in
a data-driven manner. By contrast, we allow the user to set the number of
studies n that a gene is required to be captured by, and we study how the
expected true positive proportion and false discovery rates are affected by
which alternative is considered to hold. Our interest is in scenarios where
the alternative hypothesis is the same across studies, as is often the case in
genomic studies.
In another approach to the problem, Lu, Gamst and Xu (2008) develop
a bootstrap methodology for assessing the average frequency with which
significant genes will be rediscovered under independent validation. This
approach is useful at the end of a study when significant gene-lists have
been identified, and no external validation data set is available. In particu-
lar, it can be used to estimate the internal stability of discovered genes, and
also to compare different ranking procedures applied within the same study.
Our focus is on external validation. We aim to provide a formal statisti-
cal method for evaluating genes that replicate across multiple studies. We
discuss how one might a priori choose within-study significance thresholds
(i.e., r) and cross-study recapture rates (i.e., n) to ensure (i) adequate prob-
ability of capturing true positives, and (ii) low false discovery rate within
the recaptured set, when designing a bioinformatic search across multiple
genomic data sets. After this search is complete, our methods can be applied
to obtain p-values for observed recaptured sets, although permutation tests
could also be used to obtain p-values, while the bootstrap could be used to
obtain distributions of test statistics.
Our approach has some limitations. We assume that the threshold r for
determining high-ranking genes is the same for all studies, as are the cor-
responding probabilities p0 of selecting a null gene (used in computing p-
values) and pa of selecting a differentially expressed gene (used in computing
the expected proportion of true positives for study design). These assump-
tions could be relaxed computationally, although the distributional calcula-
tions would lose their simple closed form solutions. Often when comparing
results across studies the technology used to generate the data will be simi-
lar, in which case requiring similar parameters across studies should not pose
a serious problem. In fact, this assumption is analogous to the homogeneity
test in meta-analysis where only studies with similar design, populations,
and measurement methods are pooled. Further, as with many methods in
common use in the analysis of gene-expression data, our calculations assume
that genes are independent, which is unlikely to be the case in practice, as
discussed in Section 6.1. As with any analysis of gene-expression data using
microarrays, RNA-seq, or other technologies, it is expected that results will
be independently verified using different experimental methods.
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In summary, in this article we describe a simple and rigorous inferential
method for evaluating the consistency of results across multiple independent
studies, using a combined type I error for discovery of a significant gene set,
and an estimated FDR within the gene set. We show how to choose study
parameters to maximize the expected number of significant genes that will
be captured. Future work will consider related approaches which are based
on FDR control. The framework we describe for selecting a significant set
of genes is used widely by biologists and bioinformaticians [Tomlins et al.
(2005), Pyne, Futcher and Skiena (2006), Benjamini, Heller and Yekutieli
(2009), Glez-Pena et al. (2008), Culhane et al. (2010)]. We hope that pro-
viding a simple computational and statistical underpinning for such studies
will lead to more formal use of these methods with corresponding improved
control of type I error rates.
SUPPLEMENTARY MATERIAL
Online supplement: Statistical tests for the intersection of independent
lists of genes (DOI: 10.1214/11-AOAS510SUPP; .pdf). Simulation studies
and proofs are in the online supplement. In Section S1 we show by simu-
lation that the Poisson approximation to the null distribution of the test
statistic gives reliable p-values under a wide range of parameters, both for
the independent case (Section S1.1) and under a range of moderate positive
correlation structures (Section S1.2). We confirm that the Poisson approxi-
mation computed under assumed independence yields conservative p-values
under examples of extreme positive correlation, as conjectured in the text
(Section 6.1). In Section S2 we derive the alternative distribution of the
test statistic for some useful special cases, using combinatorial results Feller
(1957).
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